Novel vaccine strategies to induce respiratory mucosal immunity: advances and implications

Abstract

Rapid advances in vaccine technology are becoming increasingly important in tackling global health crises caused by respiratory virus infections. While traditional vaccines, primarily administered by intramuscular injection, have proven effective, they often fail to provide the broad upper respiratory tract mucosal immunity, which is urgently needed for first-line control of respiratory viral infections. Furthermore, traditional intramuscular vaccines may not adequately address the immune escape of emerging virus variants. In contrast, respiratory mucosal vaccines developed using the body’s mucosal immune response mechanism can simultaneously establish both systemic and mucosal immunity. This dual action effectively allows the respiratory mucosal immune system to function as the first line of defense, preventing infections at the entry points. This review highlights the efficacy of respiratory mucosal vaccines, including innovative delivery methods such as nasal and oral formulations, in enhancing local and systemic immune barriers. Notably, respiratory mucosal vaccines offer potential advantages in protecting against emerging virus variants and maintaining long-term and multidimensional immune memory in the upper respiratory tract. In addition, a combination of intramuscular and respiratory mucosal delivery of vaccines largely improves their coverage and effectiveness, providing valuable insights for future vaccine development and public inoculation strategies.

Keywords

multidimensional immune protection / respiratorymucosal vaccines / respiratory virus infection

References

[1] Clementi N, Ghosh S, De Santis M, et al. Viral respiratory pathogens and lung injury. Clin Microbiol Rev. 2021; 34(3): e00103-20.

[2] Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull Hist Med. 2002; 76(1): 105-115.

[3] Lue JF. The severe acute respiratory syndrome. N Engl J Med. 2004; 350(17): 1797.

[4] Who Mers-Cov Research G. State of knowledge and data gaps of middle east respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr. 2013; 5.

[5] Yu XJ, Liang MF, Zhang SY, et al. Fever with Thrombocytopenia Associated with a Novel Bunyavirus in China. New England Journal of Medicine. 2011; 364(16): 1523-1532.

[6] Lian YB, Hu MJ, Guo TK, et al. The protective effect of intranasal immunization with influenza virus recombinant adenovirus vaccine on mucosal and systemic immune response. Int Immunopharmacol. 2024; 130: 111710.

[7] Noguchi K. RSV vaccine in older adults. S D Med. 2023; 76(12): 566-569.

[8] Pilapitiya D, Wheatley AK, Tan HX. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience. EBioMedicine. 2023; 92: 104585.

[9] Linden SK, Sutton P, Karlsson NG, et al. Mucins in the mucosal barrier to infection. Mucosal Immunol. 2008; 1(3): 183-197.

[10] Lavelle EC, Ward RW. Mucosal vaccines—fortifying the frontiers. Nat Rev Immunol. 2022; 22(4): 236-250.

[11] Miquel-Clopes A, Bentley EG, Stewart JP, Carding SR. Mucosal vaccines and technology. Clin Exp Immunol. 2019; 196(2): 205-214.

[12] Skwarczynski M, Toth I. Non-invasive mucosal vaccine delivery: advantages, challenges and the future. Expert Opin Drug Deliv. 2020; 17(4): 435-437.

[13] Ma B, Tao M, Li Z, Zheng Q, Wu H, Chen P. Mucosal vaccines for viral diseases: status and prospects. Virology. 2024; 593: 110026.

[14] Hellings PW, Steelant B. Epithelial barriers in allergy and asthma. J Allergy Clin Immunol. 2020; 145(6): 1499-1509.

[15] Moutsopoulos NM, Konkel JE. Tissue-specific immunity at the oral mucosal barrier. Trends Immunol. 2018; 39(4): 276-287.

[16] Allaire JM, Crowley SM, Law HT, Chang SY, Ko HJ, Vallance BA. The intestinal epithelium: central coordinator of mucosal immunity: (Trends in Immunology 39, 677–696, 2018). Trends Immunol. 2019; 40(2): 174.

[17] Kuek LE, Lee RJ. First contact: the role of respiratory cilia in host-pathogen interactions in the airways. Am J Physiol Lung Cell Mol Physiol. 2020; 319(4): L603-L619.

[18] Gallo O, Locatello LG, Mazzoni A, Novelli L, Annunziato F. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. Mucosal Immunol. 2021; 14(2): 305-316.

[19] Vesala L, Hultmark D, Valanne S. Editorial: recent advances in drosophila cellular and humoral innate immunity. Front Immunol. 2020; 11: 598618.

[20] Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014; 14(1): 36-49.

[21] Kawamura T, Ogawa Y, Aoki R, Shimada S. Innate and intrinsic antiviral immunity in skin. J Dermatol Sci. 2014; 75(3): 159-166.

[22] Agostinis C, Mangogna A, Balduit A, et al. COVID-19, pre-eclampsia, and complement system. Front Immunol. 2021; 12: 775168.

[23] Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I—molecular mechanisms of activation and regulation. Front Immunol. 2015; 6: 262.

[24] Netea MG, Joosten LA, Latz E, et al. Trained immunity: a program of innate immune memory in health and disease. Science. 2016; 352(6284): aaf1098.

[25] Netea MG, Joosten LAB. Trained immunity and local innate immune memory in the lung. Cell. 2018; 175(6): 1463-1465.

[26] Whitsett JA, Alenghat T. Respiratory epithelial cells orchestrate pulmonary innate immunity. Nat Immunol. 2015; 16(1): 27-35.

[27] Gyssens IC, Netea MG. Heterologous effects of vaccination and trained immunity. Clin Microbiol Infect. 2019; 25(12): 1457-1458.

[28] Wen W, Su W, Tang H, et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov. 2020; 6: 31.

[29] Ramirez SI, Faraji F, Hills LB, et al. Immunological memory diversity in the human upper airway. Nature. 2024.

[30] Divangahi M, Aaby P, Khader SA, et al. Trained immunity, tolerance, priming and differentiation: distinct immunological processes. Nat Immunol. 2021; 22(1): 2-6.

[31] Lee A, Floyd K, Wu S, Fang Z, et al. BCG vaccination stimulates integrated organ immunity by feedback of the adaptive immune response to imprint prolonged innate antiviral resistance. Nat Immunol. 2024; 25(1): 41-53.

[32] Debisarun PA, Gossling KL, Bulut O, et al. Induction of trained immunity by influenza vaccination—impact on COVID-19. PLoS Pathog. 2021; 17(10): e1009928.

[33] Rogier EW, Frantz AL, Bruno ME, Kaetzel CS. Secretory IgA is concentrated in the outer layer of colonic mucus along with gut bacteria. Pathogens. 2014; 3(2): 390-403.

[34] Pabst O. New concepts in the generation and functions of IgA. Nat Rev Immunol. 2012; 12(12): 821-832.

[35] Steffen U, Koeleman CA, Sokolova MV, et al. IgA subclasses have different effector functions associated with distinct glycosylation profiles. Nat Commun. 2020; 11(1): 120.

[36] Keller JK, Dulovic A, Gruber J, et al. SARS-CoV-2 specific sIgA in saliva increases after disease-related video stimulation. Sci Rep. 2023; 13(1): 22631.

[37] Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine. 2007; 25(30): 5467-5484.

[38] Corthesy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol. 2013; 4: 185.

[39] Sheikh-Mohamed S, Isho B, Chao GYC, et al. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal Immunol. 2022; 15(5): 799-808.

[40] Brokstad KA, Cox RJ, Olofsson J, Jonsson R, Haaheim LR. Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis. 1995; 171(1): 198-203.

[41] Tioni MF, Jordan R, Pena AS, et al. Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2. NPJ Vaccines. 2022; 7(1): 85.

[42] Tarke A, Sidney J, Kidd CK, et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med. 2021; 2(2): 100204.

[43] Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science. 1996; 272(5258): 50-53.

[44] Kumar BV, Ma W, Miron M, et al. Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites. Cell Rep. 2017; 20(12): 2921-2934.

[45] Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. Nat Rev Immunol. 2013; 13(5): 309-320.

[46] Szabo PA, Miron M, Farber DL. Location, location, location: tissue resident memory T cells in mice and humans. Sci Immunol. 2019; 4(34):eaas9673

[47] Pizzolla A, Nguyen THO, Smith JM, et al. Resident memory CD8 T cells in the upper respiratory tract prevent pulmonary influenza virus infection. Science Immunology. 2017; 2(12):eaam6970

[48] Zens KD, Chen JK, Farber DL. Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight. 2016; 1(10):e85832

[49] Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015; 15(3): 160-171.

[50] Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021; 19(7): 409-424.

[51] Nelson MI, Holmes EC. The evolution of epidemic influenza. Nat Rev Genet. 2007; 8(3): 196-205.

[52] Tang J, Zeng C, Cox TM, et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci Immunol. 2022; 7(76): eadd4853.

[53] Azzi L, Dalla Gasperina D, Veronesi G, et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. Ebiomedicine. 2022; 75.

[54] Liew F, Talwar S, Cross A, et al. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine. 2023; 87: 104402.

[55] Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest. 2004; 113(7): 998-1007.

[56] Zhang X, Wu S, Liu J, et al. A mosaic nanoparticle vaccine elicits potent mucosal immune response with significant cross-protection activity against multiple SARS-CoV-2 sublineages. Adv Sci (Weinh). 2023; 10(27): e2301034.

[57] Fu W, Guo M, Zhou X, et al. Injectable hydrogel mucosal vaccine elicits protective immunity against respiratory viruses. ACS Nano. 2024; 18(17): 11200-11216.

[58] Boley PA, Lee CM, Schrock J, et al. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines. J Nanobiotechnology. 2023; 21(1): 60.

[59] Hartwell BL, Melo MB, Xiao P, et al. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity. Sci Transl Med. 2022; 14(654): eabn1413.

[60] Zheng B, Peng W, Guo M, et al. Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19. Chem Eng J. 2021; 418: 129392.

[61] Ke Y, Zhang E, Guo J, et al. Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSV(MT)) in golden syrian hamster. Acta Pharm Sin B. 2023; 13(12): 4856-4874.

[62] van der Ley PA, Zariri A, van Riet E, Oosterhoff D, Kruiswijk CP. An intranasal OMV-Based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection. Front Immunol. 2021; 12: 781280.

[63] An X, Martinez-Paniagua M, Rezvan A, et al, Varadarajan N. Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. iScience. 2021; 24(9): 103037.

[64] Stauft CB, Selvaraj P, D’Agnillo F, et al. Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants. Nat Commun. 2023; 14(1): 3393.

[65] Xu F, Wu S, Yi L, et al. Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques. Emerg Microbes Infect. 2022; 11(1): 438-441.

[66] Li JX, Wu SP, Guo XL, T et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. 2022; 10(8): 739-748.

[67] Zhu F, Zhuang C, Chu K, et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med. 2022; 10(8): 749-760.

[68] Deng S, Liu Y, Tam RC, et al, Chen H. An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters. Nat Commun. 2023; 14(1): 2081.

[69] Chen J, Wang P, Yuan L, et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci Bull (Beijing). 2022; 67(13): 1372-1387.

[70] Sunagar R, Prasad SD, Ella R, Vadrevu KM. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152). Front Immunol. 2022; 13: 1063679.

[71] Singh C, Verma S, Reddy P, et al. Phase III pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin((R))). NPJ Vaccines. 2023; 8(1): 125.

[72] Le Nouen C, Nelson CE, Liu X, et al. Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys. Cell. 2022; 185(25): 4811-4825 e4817.

[73] Honda T, Toyama S, Matsumoto Y, et al. Intranasally inoculated SARS-CoV-2 spike protein combined with mucoadhesive polymer induces broad and long-lasting immunity. Vaccines (Basel). 2024; 12(7): 794.

[74] Langel SN, Johnson S, Martinez CI, et al. Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model. Sci Transl Med. 2022; 14(658): eabn6868.

[75] Mao J, Eom GD, Yoon KW, Kang HJ, Chu KB, Quan FS. Sublingual vaccination with live influenza virus induces better protection than oral immunization in mice. Life (Basel). 2022; 12(7): 975

[76] Kim Y, Park IH, Shin J, et al. Sublingual dissolving microneedle (SLDMN)-based vaccine for inducing mucosal immunity against SARS-CoV-2. Adv Healthc Mater. 2023; 12(26): e2300889.

[77] Johnson S, Martinez CI, Tedjakusuma SN, et al. Oral vaccination protects against severe acute respiratory syndrome coronavirus 2 in a Syrian hamster challenge model. J Infect Dis. 2022; 225(1): 34-41.

[78] Lapuente D, Fuchs J, Willar J, et al. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nat Commun. 2021; 12(1): 6871.

[79] Chen S, Zhang Z, Wang Q, et al. Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies. Signal Transduct Target Ther. 2024; 9(1): 190.

[80] Mao T, Israelow B, Pena-Hernandez MA, et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science. 2022; 378(6622): eabo2523.

[81] Zhang Y, Liu J, Li H, et al. Comparison of the immunogenicity of nasal-spray rVSV vector, adenovirus vector, and inactivated COVID-19-based vaccines in rodent models. J Med Virol. 2023; 95(5): e28806.

[82] Xu H, Cai L, Hufnagel S, Cui Z. Intranasal vaccine: factors to consider in research and development. Int J Pharm. 2021; 609: 121180.

[83] Mokabari K, Iriti M, Varoni EM. Mucoadhesive vaccine delivery systems for the oral mucosa. J Dent Res. 2023; 102(7): 709-718.

[84] Shim S, Soh SH, Im YB, et al. Elicitation of Th1/Th2 related responses in mice by chitosan nanoparticles loaded with Brucella abortus malate dehydrogenase, outer membrane proteins 10 and 19. Int J Med Microbiol. 2020; 310(1): 151362.

[85] Illum L. Nasal drug delivery: new developments and strategies. Drug Discovery Today. 2002; 7(23): 1184-1189.

[86] Li M, Wang Y, Sun Y, Cui H, Zhu SJ, Qiu HJ. Mucosal vaccines: strategies and challenges. Immunol Lett. 2020; 217: 116-125.

[87] Ye T, Jiao Z, Li X, et al. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature. 2023; 624(7992): 630-638.

[88] Yang J, Liu MQ, Liu L, et al. A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern. Cell Mol Immunol. 2022; 19(11): 1279-1289.

[89] Yang J, Liu MQ, Liu L, et al. The protective nasal boosting of a triple-RBD subunit vaccine against SARS-CoV-2 following inactivated virus vaccination. Signal Transduct Target Ther. 2023; 8(1): 151.

[90] Li X, Xu M, Yang J, et al. Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1. Signal Transduct Target Ther. 2024; 9(1): 114.

[91] Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol. 2012; 12(8): 592-605.

[92] Yan H, Chen W. The promise and challenges of cyclic dinucleotides as molecular adjuvants for vaccine development. Vaccines (Basel). 2021; 9(8): 917

[93] Hellfritzsch M, Scherliess R. Mucosal vaccination via the respiratory tract. Pharmaceutics. 2019; 11(8): 375

[94] Al-Halifa S, Gauthier L, Arpin D, Bourgault S, Archambault D. Nanoparticle-based vaccines against respiratory viruses. Front Immunol. 2019; 10: 22.

[95] Wu X, Li W, Rong H, Pan J, et al. A nanoparticle vaccine displaying conserved epitopes of the preexisting neutralizing antibody confers broad protection against SARS-CoV-2 variants. ACS Nano. 2024; 18(27): 17749-17763.

[96] Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021; 6(12): 1078-1094.

[97] Baldeon Vaca G, Meyer M, Cadete A, et al. Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection. Sci Adv. 2023; 9(38): eadh1655.

[98] Chakraborty C, Bhattacharya M, Lee SS. Current status of microneedle array technology for therapeutic delivery: from bench to clinic. Mol Biotechnol. 2023; 66(12): 3415-3437.

[99] Liu J, Dai S, Wang M, Hu Z, Wang H, Deng F. Virus like particle-based vaccines against emerging infectious disease viruses. Virol Sin. 2016; 31(4): 279-287.

[100] Hassan AO, Kafai NM, Dmitriev IP, et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. 2020; 183(1): 169-184 e113.

[101] Kiyono H, Azegami T. The mucosal immune system: from dentistry to vaccine development. Proc Jpn Acad Ser B Phys Biol Sci. 2015; 91(8): 423-439.

[102] Allie SR, Bradley JE, Mudunuru U, et al. The establishment of resident memory B cells in the lung requires local antigen encounter. Nat Immunol. 2019; 20(1): 97-108.

[103] Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006; 6(2): 148-158.

[104] Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD. Risk in vaccine research and development quantified. PLoS One. 2013; 8(3): e57755.

[105] Shrotri M, Swinnen T, Kampmann B, Parker EPK. An interactive website tracking COVID-19 vaccine development. Lancet Glob Health. 2021; 9(5): e590-e592.

[106] Alturaiki W. Considerations for novel COVID-19 mucosal vaccine development. Vaccines (Basel). 2022; 10(8): 1173

[107] Anggraeni R, Ana ID, Wihadmadyatami H. Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants. Clin Exp Vaccine Res. 2022; 11(3): 235-248.

[108] Savelkoul HF, Ferro VA, Strioga MM, Schijns VE. Choice and design of adjuvants for parenteral and mucosal vaccines. Vaccines (Basel). 2015; 3(1): 148-171.

[109] Wang S, Liang B, Wang W, et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023; 8(1): 149.

[110] See P, Lum J, Chen J, Ginhoux F. A single-cell sequencing guide for immunologists. Front Immunol. 2018; 9: 2425.

[111] Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021; 384(22): 2092-2101.

[112] Xu K, Duan S, Wang W, O et al. Nose-to-brain delivery of nanotherapeutics: transport mechanisms and applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024; 16(2): e1956.

[113] Trombetta CM, Gianchecchi E, Montomoli E. Influenza vaccines: evaluation of the safety profile. Hum Vaccin Immunother. 2018; 14(3): 657-670.

[114] Sasaki E, Kuramitsu M, Momose H, et al. A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests. Vaccine. 2017; 35(5): 821-830.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.